Adventrx Partners With Veterans Affairs

Adventrx Pharmaceuticals has signed a cooperative R&D agreement with the Department of Veterans Affairs (VA) that permits VA clinical sites to participate in a Phase III trial of ANX-510 for the treatment of metastatic colorectal cancer.

To be conducted at up to 100 sites across the U.S. and in other countries, the randomized trial will test progression-free survival in 1,200 subjects. Patients will be given ANX-510 (CoFactor) or leucovorin, each in combination with bevacizumab (Avastin) and 5-fluorouracil (5-FU).

CoFactor is designed to replace leucovorin as the preferred method of reducing associated toxicity of 5-FU, a cancer chemotherapy agent, according to Adventrx.